Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Urinary Bladder Neoplasms 3Neoplasm Metastasis 2Thymoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Muscle Invasive Bladder Urothelial Carcinoma 1Melanoma 1Lymphatic Metastasis 1Head and Neck Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 10 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1

Interventions

Carboplatin 11atezolizumab 10Etoposide 9durvalumab 6Topotecan 6PM 01183 6Specimen Handling 4pembrolizumab 3Magnetic Resonance Spectroscopy 3Irinotecan 2Injections 2Drug Therapy 2Cisplatin 2Biopsy 2AMG 757 2tremelimumab 1trastuzumab deruxtecan 1toripalimab 1olaparib 1lenvatinib 1fludarabine 1enzalutamide 1cabozantinib 1berzosertib 1avelumab 1arginine decarboxylase 1amrubicin 1Vaccines 1Taxes 1Sodium Chloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × avelumab × 30 days × Clear all
NCT06228066 2026-06-05

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
45 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡